Comparative Pharmacology
Head-to-head clinical analysis: PBZ versus PROMETH FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PBZ versus PROMETH FORTIS.
PBZ vs PROMETH FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PBZ (phenylbutazone) is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. It also has uricosuric effects.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, with additional anticholinergic, antiemetic, and sedative properties. It blocks histamine at H1 receptors, reducing allergic symptoms and motion sickness, and exerts antiemetic effects by blocking dopamine D2 receptors in the chemoreceptor trigger zone.
25-50 mg orally every 4-6 hours as needed; not to exceed 300 mg/day. For severe allergies: 25 mg intramuscularly or intravenously every 4-6 hours.
Adults: 12.5-25 mg intramuscular or intravenous every 4-6 hours as needed for nausea. For severe nausea up to 50 mg IM/IV. Maximum single dose 50 mg, maximum daily dose 200 mg.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in adults; prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life: 9–16 hours (mean ~12 hours). In children and elderly, half-life may be prolonged (up to 20 hours).
Renal excretion of unchanged drug (approximately 70-80%) with the remainder as metabolites. Biliary/fecal excretion accounts for <5%.
Primarily renal as inactive metabolites; <1% excreted unchanged. Total elimination: renal ~70%, fecal ~30%.
Category C
Category C
Antihistamine
Antihistamine